Revvity, Inc. (RVTY)
Revvity is a global life sciences company that provides the technology, software, and services scientists need to develop new medicines and run diagnostic tests.
Is Revvity, Inc. a good stock for a UK beginner?
The honest version: Revvity is a global life sciences company that provides the technology, software, and services scientists need to develop new medicines and run diagnostic tests.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Becoming a dominant player in precision medicine
Failure to innovate against newer, cheaper rivals
What does Revvity, Inc. do?
Revvity helps laboratories and pharmaceutical companies speed up their research and improve patient health outcomes through advanced testing equipment and data tools. The cash rolls in from selling these specialised instruments and providing ongoing support services to healthcare providers worldwide. How well they fold in their recent acquisitions will decide whether their research tools stay at the cutting edge of the industry.
On our factor screen it looks strongest on momentum and income, and weakest on growth.
- ✓Pays a dividend - about 0.2% a year
- ✓Growing - revenue up about 7% over the year
- !High P/E of 55 - big growth is already priced in
- Momentum screens high (70/100)
- Strong gross margins show they have a valuable product
- Essential role in the drug discovery and diagnostic process
- Diversified revenue streams across different healthcare sectors
- Heavy reliance on research budgets from pharmaceutical companies
- Potential for regulatory changes in diagnostic testing
- Integration challenges following past company mergers
What do Revvity, Inc.'s numbers mean?
How much money does Revvity, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Revvity, Inc. pay a dividend?
Yes - Revvity, Inc. currently pays a dividend of about 0.2% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Revvity, Inc. report earnings, and how did recent quarters go?
Revvity, Inc. is next scheduled to report on about 2026-08-04 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-05 | $1.01 | $1.06 | Beat +4% |
| 2026-02-02 | $1.58 | $1.70 | Beat +8% |
| 2025-10-27 | $1.14 | $1.18 | Beat +4% |
| 2025-07-28 | $1.14 | $1.18 | Beat +3% |
| 2025-04-28 | $0.95 | $1.01 | Beat +6% |
| 2025-01-31 | $1.38 | $1.42 | Beat +3% |
Across the last 6 quarters here, Revvity, Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Revvity, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Revvity, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong gross margins show they have a valuable product
- Essential role in the drug discovery and diagnostic process
- Diversified revenue streams across different healthcare sectors
- Current high price-to-earnings ratio suggests high expectations
- Low return on equity indicates room for better efficiency
- Modest dividend yield may not appeal to income-focused investors
- Heavy reliance on research budgets from pharmaceutical companies
- Potential for regulatory changes in diagnostic testing
- Integration challenges following past company mergers
The write-up's own warning lights — if these start happening, the case above changes.
- A significant drop in global pharmaceutical research spending
- Loss of key patents or technological advantages to competitors
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.